RNS

RNS Number : 2758U MaxCyte, Inc. 01 December 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 December 2021 :       MaxCyte (LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to

RNS Number : 2493T MaxCyte, Inc. 23 November 2021         MaxCyte, Inc.   (" MaxCyte " or the "Company")   Purchase of Common Stock - PDMR dealing   Gaithersburg, Maryland , November 23, 2021   -  M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused

RNS Number : 7413S MaxCyte, Inc. 17 November 2021         MaxCyte, Inc.   (" MaxCyte " or the "Company")   Exercise of options, PDMR dealing and Total Voting Rights   Gaithersburg, Maryland , November 17, 2021   -  M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial

RNS Number : 0207S MaxCyte, Inc. 11 November 2021         MaxCyte Reports Third Quarter Financial Results   GAITHERSBURG, MD , November 11, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to

RNS Number : 2161R MaxCyte, Inc. 03 November 2021         MaxCyte Board Member Richard Douglas , PhD, Appointed Independent Chairman of the Board   GAITHERSBURG, MD , Nov. 3, 2021   - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on

RNS Number : 7940Q MaxCyte, Inc. 29 October 2021       Result of AGM   GAITHERSBURG, MD , October 29, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research

RNS Number : 6206Q MaxCyte, Inc. 28 October 2021             MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs   Nkarta to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform to accelerate the development of its oncology

RNS Number : 2022Q MaxCyte, Inc. 26 October 2021   MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021   GAITHERSBURG, MD , October 26, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling

RNS Number : 1277O MaxCyte, Inc. 06 October 2021   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name   MAXCYTE, INC.   UK or Non- UK Issuer Non- UK   2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or

RNS Number : 8000N MaxCyte, Inc. 01 October 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Annual General Meeting   Change of Director   Gaithersburg, Maryland - 1 October 2021 :       MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company